ACTRN12622001450707招募中未知
Investigating the use of biomarkers to predict pregnancy and long term cardiovascular complications in women who develop elevated blood pressure, gestational diabetes, fetal growth restriction or spontaneous preterm labour during pregnancy
ational Heart Foundation0 个研究点目标入组 600 人开始时间: 2022年11月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- Female
入选标准
- •1. Pregnant women at any gestation in pregnancy AND
- •2. Women who develop elevated blood pressure >130/80 OR
- •3. Women who have developed pregnancy complications (Gestational diabetes (GDM), Hypertensive disorder of pregnancy (HDP), Fetal growth restriction(FGR) and spontaneous preterm birth(sPTB))
排除标准
- •1. Multiple pregnancy.
- •2. Pregnancy complicated by major fetal anomaly or genetic syndrome.
- •3. Maternal age less than 18 years,
- •4. Women incapable of giving valid consent (diminished understanding, non-English speaking
- •and interpreter unavailable).
- •5. Participation in a study where there is a pharmaceutical intervention that would likely modify the biomarkers under study.
研究者
相似试验
招募中
Unknown
Exploring Predictive and Prognostic Biomarkers in People with Cancer.Cancer - Any cancerCancerACTRN12623000853640Monash Health500
已完成
不适用
Study for new biomarker development in the prediction of prognosis of renal function in chronic kidney diseaseChronic kidney diseaseJPRN-UMIN000010140Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences216
招募中
不适用
Study for new biomarker development in the prediction of prognosis of renal function in chronic kidney diseaseChronic kidney diseaseJPRN-UMIN000014093Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences512
已完成
不适用
Study for new biomarker development in the prediction of renal anemia progression in chronic kidney diseaseChronic kidney diseaseJPRN-UMIN000008699Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences90
已完成
不适用
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancerliver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancerJPRN-UMIN000010429EPS Corporation100